Business
ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
LOS ANGELES, June 23, 2025--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA).
About this update from Laekna, Inc.
[{"type":"image","alt":"Laekna (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA).","displaySize":"","headline":null,"caption":"Laekna (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA).","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/6666e0eb987fe968902e9b85fddc41da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oYYbCg3bLgSSMAtKLqSZAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6666e0eb987fe968902e9b85fddc41da","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2233,"height":587,"url":"https://media.zenfs.com/en/business-wire.com/5486c82f34550c9df3cdbe663c6b3636"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3ZHeAxFKbAhc48IqsasvVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5486c82f34550c9df3cdbe663c6b3636","width":960,"height":252},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aBKLlOevuJMn5krpAdiavQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5486c82f34550c9df3cdbe663c6b3636","width":1200,"height":315}}},{"type":"text","content":"- Single-dose administration of LAE102 by IV or SC injection demonstrated a favorable safety profile in the healthy participants as well as robust and ...